Fundraising FoxLilly Asia Ventures — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
PartnerHongbo Lu· solo GP
Co-investorsBay City CapitalGV (Google Ventures)LAVAlexandriaFrazier Healthcare PartnersThe Column Group+1 more
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsLAVThe Capital Partnership
PartnerHongbo Lu· solo GP
Co-investorsForesite CapitalLAVNextech InvestSv Tech Ventures, Inc.HBM PartnersSR One Capital Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.